Academy for Health and Productivity Measurement. Productivity gains from RX treatment of allergies outweigh the cost of non-sedating antihistamines. Acacdemy Briefs.
American College of Allergy, Asthma and Immunology. Instruments for measuring Quality of life and performance impairment in allergic rhinitis. Ann Allergy Asthma Immunol 2001; 86(5): insert.
Dean BB, Calimlim B, Aguilar D, Sacco P, Maykut R, Tinkelman D, impact of uncontrolled pediatric asthma on child and caregiver productivity. ISPOR 13th Annual International Meeting, Toronto, Ontario, Canada, May 3, 2008.
Murray J, Nathan R, Bronsky E, Olufade AO, Chapman D, Kramer B. Cetirizine in the management of seasonal allergic rhinitis: impact on patient health-related quality of life (HRQL), work productivity and activity impairment (WPAI). Presented 1999 Annual Meeting of the American College of Allergy Asthma and Immunology (ACAAI), November 12-17, 1999.
Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002,23 (6):391-8.
Okuda M, Crawford B, Juniper E, Leahy MJ. [Preparation of Japanese versions of rinoconjunctivitis quality of life questionnaire (RQLQ) and work productivity and activity impairment questionnaire (WPAI-AS)] Arerugi. 2003 Jul;52 Suppl 1:70-86. Japanese.
Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol. 2005;136(2):148-154 [Epub ahead of print].
Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clinical Drug Investigations 1996; 11(5):278-288. Please note there is an error in the sample size calculations. We state (page 287) that 201 patients per treatment group would be required to detect a 5% difference in overall work impairment and 1,256 patients would be required to detect a 2% difference. The numbers should be 190 patients and 1,180 patients, respectively. For overall classroom impairment, the sample size per treatment group should be 290 patients, not 192 patients.
Sullivan SD, Wertz DA, Pollack M, Bohn R, Sacco P. Impact of asthma control on sleep, attendance at work, normal activities and burden of illness. Academy of Managed Care Pharmacy, 20th annual meetting, April 16-18, 2008: San Francisco, CA.
Tan H, Sarawate C, Singer J, Elward K, Cohen RI, Smart BA, Busk MF, Lustig J, O'Brien JD, Schatz M. Impact of asthma controller medications on clinical,economic, and patient-reported outcomes. Mayo Clin Proc 2009;84(8):675-84.
Tanner LA, Reilly M, Meltzer EO, Bradford JE, Mason J. Effect of fexofenadine HCI on quality of life and work, classroom and daily activity impairment in patients with seasonal allergic rhinitis. Am J Man Care 1999; 5 (suppl):S235-S247.
Brown M, Feagan B, Gerlier L, Schreiber S. Treatment with certolizumob pegol 400 mg improves work productivity and daily activities in patients with Crohn’s disease: PRECISE 2 data. Amer J Gastroent. 2006: 101 (s2). (Abstract)
Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab Induces Deep Remission in Patients with Crohn's Disease. Clin Gastroenterol Hepatol. 2013 Jul 12.
Reilly MC, Brown MCJ, Brabant Y, et al. Minimally important difference for WPAI:CD scores: Defining relevant impact on work productivity in active Crohn’s disease (Abst 962). Presented at the American College of Gastroenterology Annual Scientific Meeting; Philadelphia. October 12 to 17, 2007.
Reilly MC, Gerlier L, Brown, M. Discriminant validity of the Work Productivity and Activity Impairment questionnaire in patient’s with Crohn’s disease. Value in Health. 2006; 9(6):A246. (Abstract.)
Thomsen OØ, Brown M, Purcaru, Schreiber. Relationship between work productivity, daily activities and clinical endpoints in Crohn’s disease: data from Precise 2. Amer J Gastroent. 2006:101(s2). (Abstract)
Wladysiuk M., Bebrysz M., Fedyna M., Haldas M., Rutkowski J. What determines work productivity loss in rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis (Ps) in Poland. Results of Move to Work (M2W) study. Presented ISPOR 19th Annual International Meeting, May 31-June 4 2014, Montreal, Canada.
Wladysiuk M., Fedyna M., Haldas M., Rutkowski J., Bebrysz M. Indirect costs of rheumatoid arthritis, Crohn’s disease and psoriasis in Poland. Presented HTAi 11th Annual Meeting, Jun 16-18, Washington DC, USA.
